This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (5)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Dermatology  • General Rhinology  • Immunology  • Alert me on articles by topic  Social Bookmarking   What's this?

Yoshihiro Ohashi, MD; Yoshiaki Nakai, MD; Ayaki Tanaka, MD; Yasushi Kakinoki, MD; Yoshiharu Ohno, MD; Tateo Masamoto, MD; Hirokazu Sakamoto, MD; Akifumi Kato, MD; Yushi Washio, MD; Koji Yamada, MD; Motoyo Hayashi, MD

Arch Otolaryngol Head Neck Surg. 1998;124:41-45.

Background  Soluble forms of intercellular adhesion molecule-1 (sICAM-1) and vascular cell adhesion molecule-1 (sVCAM-1) have recently been identified in serum samples from atopic patients, but their clinical significance in the treatment of allergic diseases remains to be established.

Objective  To study the clinical roles of serum sICAM-1 and sVCAM-1 during immunotherapy for perennial allergic rhinitis.

Design  Our study included 30 nonatopic volunteers and 60 patients with perennial allergic rhinitis due to Dermatophagoides farinae. The 60 patients had been treated for variable periods (7.3±3.0 years [mean±SD]) with immunotherapy using a standardized D farinae antigen. Serum samples were collected from each patient before and after immunotherapy to determine sICAM-1 and sVCAM-1 with sandwich enzyme-linked immunosorbent assays.

Results  Serum levels of sICAM-1 in the patients before immunotherapy were higher than those in the nonatopic volunteers (P<.001). The levels of sICAM-1 in the patients' serum samples were decreased significantly after immunotherapy (P<.001), and the percentage of the decrease in the sICAM-1 levels was significantly correlated with the duration of immunotherapy (P=.04) and with the percentage of the decrease in symptom scores (P<.001). The levels of sVCAM-1 in the serum samples from the patients with severe symptoms were significantly higher before immunotherapy than those in the nonatopic volunteers (P=.002) and were significantly decreased after immunotherapy (P=.05). However, the percentage of the decrease in the sVCAM-1 levels was not correlated with the duration of immunotherapy (P=.89) or with the percentage of the decrease in symptom scores (P=.89).

Conclusion  Decrease in serum sICAM-1 levels during immunotherapy is probably involved in the working mechanisms of immunotherapy, but modulation of serum sVCAM-1 levels is not likely related to the clinical effect of immunotherapy.

From the Department of Otolaryngology, Osaka City University Medical School, Osaka, Japan.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Serologic Study of the Working Mechanisms of Immunotherapy for Children With Perennial Allergic Rhinitis
Ohashi et al.
Arch Otolaryngol Head Neck Surg 1998;124:1337-1346.
ABSTRACT | FULL TEXT